Soligenix (NASDAQ:SNGX) spotted trading -66.73% off 52-week high price. On the other end, the stock has been noted 12.60% away from the low price over the last 52-weeks. The stock changed 4.42% to recent value of $0.73. The stock transacted 81831 shares during most recent day however it has an average volume of 114.87K shares. The company has 17.62M of outstanding shares and 16.31M shares were floated in the market.
Soligenix (NASDAQ:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, declared that Soligenix will be participating in a biodefense contract for the development of medical countermeasures against bacterial threat agents, with Soligenix awarded a subcontract of approximately $600,000 over 3 years.
Innate Defense Regulators (IDRs) regulate the innate immune system to simultaneously reduce inflammation, eliminate infection and enhance tissue healing. IDRs have no direct antibiotic activity but modulate host responses, increasing survival after infections with a broad range of bacterial Gram-negative and Gram-positive pathogens including both antibiotic sensitive and resistant strains, as well as accelerating resolution of tissue damage following exposure to a variety of agents including bacterial pathogens, trauma and chemo- or radiation-therapy. IDRs are also effective in conjunction with antibiotics, enhancing efficacy of sub-optimal antibiotic regimens and reducing the required antibiotic dose, thereby potentially minimizing the generation of antibiotic resistance. Soligenix has previously reported the results of a Phase 2 clinical study using dusquetide, its lead IDR, in the treatment of oral mucositis in head and neck cancer patients undergoing chemoradiation therapy. In addition to demonstrating a reduction in the median duration of severe oral mucositis in these patients, dusquetide treatment was also associated with a reduced incidence of reported infections. A pivotal Phase 3 multinational study in oral mucositis is currently underway in the U.S. and Europe, with an interim analysis expected in the September 2019 timeframe.
The proposed work will further evaluate the efficacy of the IDR platform in animal models of disease caused by bacterial biothreat agents, such as B. pseudomallei and F. tularensis, among others. Previous animal studies have demonstrated efficacy against B. pseudomallei infection.
Its earnings per share (EPS) expected to touch remained 41.90% for this year while earning per share for the next 5-years is expected to reach at 1.00%. SNGX has a gross margin of 13.70% and .
According to the most recent quarter its current ratio was 2.2 that represents company’s ability to meet its current financial obligations. The price moved ahead of 0.78% from the mean of 20 days, -10.58% from mean of 50 days SMA and performed -32.99% from mean of 200 days price. Company’s performance for the week was -0.83%, 1.68% for month and YTD performance remained -14.88%.